Vistagen Reports Second Quarter Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
VistaGen Therapeutics (VTGN) Misses Q2 EPS by 1c
November 10, 2022 4:31 PM ESTVistaGen Therapeutics (NASDAQ: VTGN) reported Q2 EPS of ($0.08), $0.01 worse than the analyst estimate of ($0.07).
For earnings history and earnings-related data on VistaGen Therapeutics (VTGN) click here.
... More